236 related articles for article (PubMed ID: 18082495)
1. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
Thomas KL; Al-Khatib SM; Lokhnygina Y; Solomon SD; Kober L; McMurray JJ; Califf RM; Velazquez EJ
Am Heart J; 2008 Jan; 155(1):87-93. PubMed ID: 18082495
[TBL] [Abstract][Full Text] [Related]
2. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
3. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
[TBL] [Abstract][Full Text] [Related]
5. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
[TBL] [Abstract][Full Text] [Related]
6. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
Thune JJ; Signorovitch JE; Kober L; McMurray JJ; Swedberg K; Rouleau J; Maggioni A; Velazquez E; Califf R; Pfeffer MA; Solomon SD
Eur J Heart Fail; 2011 Feb; 13(2):148-53. PubMed ID: 21037250
[TBL] [Abstract][Full Text] [Related]
7. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
[TBL] [Abstract][Full Text] [Related]
8. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Shamshad F; Kenchaiah S; Finn PV; Soler-Soler J; McMurray JJ; Velazquez EJ; Maggioni AP; Califf RM; Swedberg K; Kober L; Belenkov Y; Varshavsky S; Pfeffer MA; Solomon SD;
Am Heart J; 2010 Jul; 160(1):145-51. PubMed ID: 20598985
[TBL] [Abstract][Full Text] [Related]
9. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
[TBL] [Abstract][Full Text] [Related]
10. Long-term significance of Killip class and left ventricular systolic dysfunction.
Parakh K; Thombs BD; Bhat U; Fauerbach JA; Bush DE; Ziegelstein RC
Am J Med; 2008 Nov; 121(11):1015-8. PubMed ID: 18954850
[TBL] [Abstract][Full Text] [Related]
11. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Anavekar NS; McMurray JJ; Velazquez EJ; Solomon SD; Kober L; Rouleau JL; White HD; Nordlander R; Maggioni A; Dickstein K; Zelenkofske S; Leimberger JD; Califf RM; Pfeffer MA
N Engl J Med; 2004 Sep; 351(13):1285-95. PubMed ID: 15385655
[TBL] [Abstract][Full Text] [Related]
12. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study.
Lewis EF; Velazquez EJ; Solomon SD; Hellkamp AS; McMurray JJ; Mathias J; Rouleau JL; Maggioni AP; Swedberg K; Kober L; White H; Dalby AJ; Francis GS; Zannad F; Califf RM; Pfeffer MA
Eur Heart J; 2008 Mar; 29(6):748-56. PubMed ID: 18308687
[TBL] [Abstract][Full Text] [Related]
13. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry.
Velazquez EJ; Francis GS; Armstrong PW; Aylward PE; Diaz R; O'Connor CM; White HD; Henis M; Rittenhouse LM; Kilaru R; van Gilst W; Ertl G; Maggioni AP; Spac J; Weaver WD; Rouleau JL; McMurray JJ; Pfeffer MA; Califf RM;
Eur Heart J; 2004 Nov; 25(21):1911-9. PubMed ID: 15522470
[TBL] [Abstract][Full Text] [Related]
14. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Reed SD; McMurray JJ; Velazquez EJ; Schulman KA; Califf RM; Kober L; Maggioni AP; Van de Werf F; White HD; Diaz R; Mareev V; Murin J;
Am Heart J; 2006 Sep; 152(3):500-8. PubMed ID: 16923421
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
Moukarbel GV; Signorovitch JE; Pfeffer MA; McMurray JJ; White HD; Maggioni AP; Velazquez EJ; Califf RM; Scheiman JM; Solomon SD
Eur Heart J; 2009 Sep; 30(18):2226-32. PubMed ID: 19556260
[TBL] [Abstract][Full Text] [Related]
16. Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus.
Anavekar NS; Solomon SD; McMurray JJ; Maggioni A; Rouleau JL; Califf R; White H; Kober L; Velazquez E; Pfeffer MA
Am J Cardiol; 2008 Apr; 101(7):925-9. PubMed ID: 18359309
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
[TBL] [Abstract][Full Text] [Related]
18. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
19. Heart attack patients with complications. Treat with valsartan, captopril, or both?
Nguyen A; Sharma S
Can Fam Physician; 2004 Aug; 50():1093-5. PubMed ID: 15455807
[No Abstract] [Full Text] [Related]
20. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction.
Shah AM; Pfeffer MA; Hartley LH; Moyé LA; Gersh BJ; Rutherford JD; Lamas GA; Rouleau JL; Braunwald E; Solomon SD
Am J Cardiol; 2010 Oct; 106(7):911-6. PubMed ID: 20854949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
